USA > France based Sanofi is set to acquire Bioverativ Inc. for approximately $11.6 billion

Sanofi logo For $105 per share in cash, Sanofi is set to acquire all the outstanding shares of Bioverativ representing an equity value of approximately $11.6 billion. Both biopharmaceutical companies focus on therapies for hemophilia and other rare blood disorders and the transaction was unanimously approved by Board of Directors of both Sanofi and Bioverativ. According to Olivier Brandicourt, Sanofi’s Chief Executive More …